283 related articles for article (PubMed ID: 17564126)
1. [Survey of anti-tuberculosis drug-induced severe liver injury in Japan].
Shigeto E;
Kekkaku; 2007 May; 82(5):467-73. PubMed ID: 17564126
[TBL] [Abstract][Full Text] [Related]
2. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
3. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
4. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
7. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
Wada M; Yoshiyama T; Ogata H; Ito K; Mizutani S; Sugita H
Kekkaku; 1999 Apr; 74(4):353-60. PubMed ID: 10355221
[TBL] [Abstract][Full Text] [Related]
8. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
[TBL] [Abstract][Full Text] [Related]
9. [Management of adverse effects with antituberculosis chemotherapy].
Tsuyuguchi K; Wada M
Kekkaku; 2011 Feb; 86(2):87-99. PubMed ID: 21404653
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
[TBL] [Abstract][Full Text] [Related]
11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
12. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of hepatic function in new cases of pulmonary tuberculosis due to the use of standard chemotherapy regimens I and IIB].
Abdullaev RIu; Vaniev EV; Kaminskaia GO; Vasil'eva IA; Komissarova OG
Probl Tuberk Bolezn Legk; 2009; (2):57-61. PubMed ID: 19382645
[TBL] [Abstract][Full Text] [Related]
14. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
15. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
16. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
17. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation].
Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M
Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
19. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Nomi F; Hosaka K; Kurosawa T
Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
[TBL] [Abstract][Full Text] [Related]
20. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
